Exiting European Medicines Agency could mean UK waits longer for coronavirus vaccine

16th March 2020 / NewsBits
  • The UK intends to leave European Medicines Agency (EMA) at the end of the transition period, scheduled for the end of the year.
  • But academics and lawyers fear a departure from the EU institution will mean that the UK will have to join a queue of non-EU countries to acquire a vaccine to the COVID-19 disease, which they predict will arrive next year.
  • Writing in the Guardian the experts are expecting that the UK will leave the European Union’s EMA, which presently allows for ‘accelerated assessment’ of products developed by drugs companies during a pandemic.
  • The government has already taken the UK out of the emergency bulk-buying mechanism for vaccines and medicines, which allows countries to strike agreements with pharmaceutical companies to speed up the process at a time of crisis.


At a time when reporting the truth is critical, your support is essential in protecting it.
Find out how

The European Financial Review

European financial review Logo

The European Financial Review is the leading financial intelligence magazine read widely by financial experts and the wider business community.